Abstract
To develop and validate a practical, in vitro, cell-based model to assess human hepatotoxicity potential of drugs, we used the new technology of high content screening (HCS) and a novel combination of critical model features, including (1) use of live, human hepatocytes with drug metabolism capability, (2) preincubation of cells for 3 days with drugs at a range of concentrations up to at least 30 times the efficacious concentration or 100 μM, (3) measurement of multiple parameters that were (4) morphological and biochemical, (5) indicative of prelethal cytotoxic effects, (6) representative of different mechanisms of toxicity, (7) at the single cell level and (8) amenable to rapid throughput. HCS is based on automated epifluorescence microscopy and image analysis of cells in a microtiter plate format. The assay was applied to HepG2 human hepatocytes cultured in 96-well plates and loaded with four fluorescent dyes for: calcium (Fluo-4 AM), mitochondrial membrane potential (TMRM), DNA content (Hoechst 33342) to determine nuclear area and cell number and plasma membrane permeability (TOTO-3). Assay results were compared with those from 7 conventional, in vitro cytotoxicity assays that were applied to 611 compounds and shown to have low sensitivity (<25%), although high specificity (∼90%) for detection of toxic drugs. For 243 drugs with varying degrees of toxicity, the HCS, sublethal, cytotoxicity assay had a sensitivity of 93% and specificity of 98%. Drugs testing positive that did not cause hepatotoxicity produced other serious, human organ toxicities. For 201 positive assay results, 86% drugs affected cell number, 70% affected nuclear area and mitochondrial membrane potential and 45% affected membrane permeability and 41% intracellular calcium concentration. Cell number was the first parameter affected for 56% of these drugs, nuclear area for 34% and mitochondrial membrane potential for 29% and membrane permeability for 7% and intracellular calcium for 10%. Hormesis occurred for 48% of all drugs with positive response, for 26% of mitochondrial and 34% nuclear area changes and 12% of cell number changes. Pattern of change was dependent on the class of drug and mechanism of toxicity. The ratio of concentrations for in vitro cytotoxicity to maximal efficaciousness in humans was not different across groups (12±22). Human toxicity potential was detected with 80% sensitivity and 90% specificity at a concentration of 30× the maximal efficacious concentration or 100 μM when efficaciousness was not considered. We conclude that human hepatotoxicity is highly concordant with in vitro cytotoxicity in this novel model and as detected by HCS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abraham VC, Taylor L, Haskins JR (2004) High content screening applied to large-scale cell biology. Trends Biotechnol 22:15–72
Andrade RJ, Carmargo R, Lucena MI, Ganzalez-Grande R (2004) Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 3:329–344
Barhoumi R, Bailey RH, Burghardt RC (1995) Kinetic analysis of glutathione in anchored cells with monochlorobimane. Cytometry 19:226–34
Bernardi P, Petronilli V, Di Lisa F, Forte M (2001) A mitochondrial perspective on cell death. Trends Biochem Sci 26:112–117
Boelsterli UA (2003a) Disease-related determinants of susceptibility to drug-induced idiosyncratic hepatotoxicity. Curr Opin Drug Discov Devel 6:81–91
Boelsterli UA (2003b) Idiosyncratic drug hepatotoxicity revisited: new insights from mechanistic toxicology. Toxicol Mech Methods 13:3–20
Brain P, Cousens R (1989) An equation to describe dose response when there is stimulation of growth at low doses. Weed Res 29:93–96
Bugelski PJ, Atif U, Molton S, Toeg I, Lord PG, Morgan, DG. (2000) A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology. Pharm Res 17:1265–72
Calabrese EJ, Baldwin LA (2002) Applications of hormesis in toxicology, risk assessment and chemotherapeutics. Trends Pharmacol Sci 23:331–337
Cerep (2005) In vitro Pharmacology and ADME-Tox Catalog Product No.900–59. Cerep, Redmond
Colombo B, Felicetti L, Baglioni C (1965) Inhibition of protein synthesis by cycloheximide in rabbit reticulocytes. Biochem Biophys Res Commun 18:389–95
Fung M, Thornton A, Mybeck K, Hsiao-Hui W, Hornbuckle K, Muniz E (2001) Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets—1960–1999. Drug Inf J 35:293 – 317
GenStat (2002) GenStat for Windows Release 6.1, 6th (edn.). VSN International Ltd, Oxford
Giuliano KA., Haskins JR, Taylor DL (2003) Advances in high content screening for drug discovery. Assay Drug Dev Technol 1:565–577
Graphpad Prism (2004) Graphpad Prism version 4.01 for Windows. Graphpad Software Inc, San Diego
Gurtu V, Kain SR, Zhang G (1997) Fluorometric and colorimetric detection of caspase activity associated with apoptosis. Anal Biochem 251:98–102
Haskins JR, Rowse P, Rahbari R, de La Iglesia FA (2001) Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 75:425–438
Jaeschke H, Gores GJ, Cedeerbau AI, Hinson JA, Pessayre D, Lemasters JJ (2002) Mechanisms of hepatotoxicity. Toxicol Sci 65:166–176
Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, O’Donnell JP, Boer J, Harriman SP (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:1–65
Kaplowitz N (2001) Drug-induced liver disorders. Implications for drug development and regulation. Drug Saf 24:483–490
Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev 4:489–499
Lee WM (2003) Drug-induced hepatotoxicity. New Engl J Med 349:474–85
Levesque A, Paquet A, Page M (1995) Improved fluorescent bioassay for the detection of tumor necrosis factor activity. J Immunol Methods 178:71–6
Lewis JH (2002) Drug-induced liver disease. Curr Opin Gastroenterol 18:307–313
Lewis W, Day BJ, Copeland WC (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2:812–822
Lorico A, Masturzo P, Villa S, Salmona M, Semeraro N, de Gaetano G (1986) Gentisic acid: an aspirin metabolite with multiple effects on human blood polymorphonuclear leukocytes. Biochem Pharmacol 35:2443–5
Meselson M, Stahl FW (1958) The replication of DNA. Cold Spring Harb Symp Quant Biol 23:9–12
Nociari MM, Shalev A, Benias P, Russo C (1998) A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods 213:157–67
O’Brien PJ, Kalow BI, Brown BD, Lumsden JH, Jacobs RM (1989) Porcine malignant hyperthermia susceptibility: halothane-induced increase in cytoplasmic free calcium of peripheral blood lymphocytes. Am J Vet Res 50:131–135
O’Brien PJ, Kalow BI, Ali N, Lassaline LA, Lumsden JH (1990) Compensatory increase in calcium extrusion activity of untreated lymphocytes from swine susceptible to malignant hyperthermia. Am J Vet Res 51:1038–1043
O’Brien PJ, Slaughter MR, Biagini C, Diaz D, Gao, B, Irwin W, Krejsa C, Hougham C, Abraham V, Haskins JR (2003) Predicting drug-induced human hepatotoxicity with in vitro cytotoxicity assays. In: Proceedings Tox ’03, London, UK
Olson H, Betton G, Stritar J, Robinson D (1998) The predictivity of the toxicity of pharmaceuticals in humans from animal data—an interim assessment. Toxicol Lett 102–103:535–538
Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56–67
Olson H, Kadyszewski E, Beierschmitt W (2001) Hormesis—a pharmaceutical industry perspective. Crit Rev Toxicol 31:659–61
Phillips GW, Irwin WA, Howard-Cofield EJ, Randle LE, Abraham V, Haskins J, O’Brien PJ (2005) Incorporation of an oxidative stress biomarker into high content screening (HCS) for human toxicity potential. Proc Soc Biomol Screen
Plymale DR, Haskins JR, De La Iglesia FA (1999) Monitoring of simultaneous subcellular events in vitro by means of coherent multiprobe fluorescence. Nat Med 5:351–355
Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P (2004) Liver transplantation for acute liver failure from drug-induced liver injury in the United States. Liver Transpl 10:1018–1023
Schoonen WGEJ, Westerink WMA, de Roos JADM, Debiton E. (2005a) Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I. Mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol In Vitro 19:505–516
Schoonen WGEJ, Westerink WMA, de Roos JADM, Debiton E. (2005b) Cytotoxic effects of 110 reference compounds on Hep G2 and for 60 compounds on HeLa, ECC-1 and CHO cells. I. Mechanistic assays on NAD(P)H, ATP, and DNA contents. Toxicol In Vitro 19:491–503
Slaughter MR, Thakkar H, O’Brien PJ (2002) Effect of diquat on the antioxidant system and cell growth in human neuroblastoma cells. Toxicol Appl Pharmacol 178:63–70
Xu JJ, Diaz D, O’Brien PJ (2004). Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 150:115–128
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O’Brien, P.J., Irwin, W., Diaz, D. et al. High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80, 580–604 (2006). https://doi.org/10.1007/s00204-006-0091-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-006-0091-3